Study record
Fisetin is a senotherapeutic that extends health and lifespan (Yousefzadeh et al., 2018)
Animal lifespan study
○ Evidence tier 5 — Animal lifespan study
Record verify: verified against primary source
| Design | Preclinical (mouse) senolytic screen + lifespan study |
| PMID | 30279143 |
| DOI | 10.1016/j.ebiom.2018.09.015 |
| Citation status | pmid+doi verified via PubMed eutils (EBioMedicine 2018;36:18-28; PMC6197652) |
Identifiers: DOI verified; PMC verified; PMID verified; trial registry id not applicable to this study type. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that cannot apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | Aged wild-type mice and progeroid mouse models; screen of 10 flavonoids. |
| Exposure, route, schedule | Oral fisetin, acute/intermittent and late-life dosing. |
| Comparator / duration | Vehicle-treated age-matched controls; wild-type arm followed for lifespan. |
| Endpoint / numeric result | Fisetin was the most potent senolytic of the flavonoids tested; reduced senescence markers in multiple tissues; late-life dosing extended median and maximum lifespan in wild-type mice. |
| What it did NOT establish | Animal result only; no human lifespan or healthspan effect established. |